A groundbreaking study led by researchers at Insilico Medicine has revealed the potential of TNIK inhibition as an innovative anti-aging strategy. Using an AI-driven robotics laboratory , the team ...
A new paper in Trends in Pharmacological Sciences from researchers at generative artificial intelligence (AI)- and robotics-powered clinical stage drug discovery company Insilico Medicine ("Insilico") ...
Researchers from artificial intelligence (AI) drug developer Insilico Medicine and two partner institutions have published a study concluding that its lead candidate ISM001-055 is the first to show ...
A new paper in Trends in Pharmacological Sciences from researchers at generative artificial intelligence (AI)- and robotics-powered clinical stage drug discovery company Insilico Medicine (“Insilico”) ...
Using an AI-driven robotics laboratory , the team identified INS018_055 (Rentosertib) —a potent small-molecule TNIK previously developed by Insilico Medicine, which has already advanced into clinical ...
Encouraging clinical data showed that patients receiving 60 mg QD Rentosertib experienced the greatest mean improvement in lung function, as measured by forced vital capacity (FVC), with a mean change ...
AI-based drug developer Insilico Medicine said it plans to advance its lead candidate ISM001-055 into a potentially pivotal study, after generating positive topline results in a Phase IIa trial ...
TRAF2- and NCK-interacting kinase (TNIK) has been reported as a therapeutic target for colorectal cancer and, more recently, for lung squamous cell carcinoma, triple-negative breast cancer, or ovarian ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results